Microenvironment-driven resistance to B-Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F18%3A00502204" target="_blank" >RIV/68378050:_____/18:00502204 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/18:10376664 RIV/00023761:_____/18:N0000015 RIV/00064165:_____/18:10376664
Result on the web
<a href="http://dx.doi.org/10.3892/ijmm.2018.3448" target="_blank" >http://dx.doi.org/10.3892/ijmm.2018.3448</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/ijmm.2018.3448" target="_blank" >10.3892/ijmm.2018.3448</a>
Alternative languages
Result language
angličtina
Original language name
Microenvironment-driven resistance to B-Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts
Original language description
The incidence of malignant melanoma is rapidly increasing and current medicine is offering only limited options for treatment of the advanced disease. For B-Raf mutated melanomas, treatment with mutation-specific drug inhibitors may be used. Unfortunately, tumors frequently acquire resistance to the treatment. Tumor microenvironment, namely cancer-associated fibroblasts, largely influence this acquired resistance. In the present study, fibroblasts were isolated from a patient suffering from acrolentiginous melanoma (Breslow, 4.0 mm, Clark, IV, B-Raf V600E mutated). The present study focused on the expression of structural and functional markers of fibroblast activation in melanoma-associated fibroblasts (MAFs, isolated prior to therapy initiation) as well as in autologous control fibroblasts (ACFs) of the same patient isolated during B-Raf inhibitor therapy, yet before clinical progression of the disease. Analysis of gene transcription was also performed, as well as DNA methylation status analysis at the genomic scale of both isolates. MAFs were positive for smooth muscle actin (SMA), which is a marker of myofibroblasts and the hallmark of cancer stoma. Surprisingly, ACF isolated from the distant uninvolved skin of the same patient also exhibited strong SMA expression. A similar phenotype was also observed in control dermal fibroblasts (CDFs, from different donors) exclusively following stimulation by transforming growth factor (TGF)-1. Immunohistochemistry confirmed that melanoma cells potently produce TGF-1. Significant differences were also identified in gene transcription and in DNA methylation status at the genomic scale. Upregulation of SMA was observed in ACF cells at the protein and transcriptional levels. The present results support recent experimental findings that tumor microenvironment is driving resistance to B-Raf inhibition in patients with melanoma. Such an activated microenvironment may be viable for the growth of circulating melanoma cells.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Molecular Medicine
ISSN
1107-3756
e-ISSN
—
Volume of the periodical
41
Issue of the periodical within the volume
5
Country of publishing house
GR - GREECE
Number of pages
17
Pages from-to
2687-2703
UT code for WoS article
000429095900025
EID of the result in the Scopus database
—